Autoimmune psychosis
In The Lancet Psychiatry, Thomas A Pollak and colleagues report their consensus on diagnosis and management of patients with psychosis of possible, probable, or definite autoimmune cause. 1 Although similar to other criteria for autoimmune encephalitis, autoimmune psychosis rarely presents as an isolated treatable entity.
Previous iterations of criteria for formes fruste of autoimmune encephalitis include those for autoimmune dementia and autoimmune epilepsy-entities proven to be treatment-responsive within 12 months of onset. 2, 3 Autoimmune dementia is an operational term for patients with immunotherapy response-confirmed rapidly progressive cognitive decline without delirium or seizures (mimicking Creuzfeldt-Jakob disease or neurodegenerative dementia). 56 (78%) of our 72 suspected cases had objective improvements in neuropsychometric or bedside cognitive measures. 2 One third of patients had been diagnosed previously with degenerative dementia. 2 Autoimmune epilepsy encompasses patients presenting with seizures, without other encephalitic features. 22 (81%) of our 27 cases were immunotherapy responsive (all had >50% seizure reduction, most were Lgi1 antibody positive, which is encephalitis specific, even if detected in serum only). 3 By contrast, Pollak and colleagues provide little cohort-based data to support criteria for isolated autoimmune psychosis as distinct from autoimmune encephalitis. 1 Accurate neurological history should distinguish rare cases of early affective symptom-predominant N-methyl-D-aspartate receptor (NMDAR) encephalitis from primary psychosis. 4 In addition, in 2015, we reported a hospital-based psychiatric cohort of 225 patients; 24 had an autoimmune cause. 5 12 had NMDAR encephalitis (antibody positive in cerebrospinal fluid), and 12 had other paraclinical findings supportive of autoimmunity. None of the patients had a phenotype resembling schizophrenia. Mood symptoms were prominent (80%), and usually preceded psychosis (present in 58%). All had prominent cognitive symptoms, a non-tardive movement disorder, or both, from the outset. All 12 patients with NMDAR encephalitis had early speech and language disorders, 75% became catatonic (not present among the other 12 patients). In our experience, multimodal neuropsychiatric presentations 2 are easily distinguishable from the typical psychiatric referral to our autoimmune neurology clinic: young adults with schizophreniform illnesses, without additional features. Some patients with atypical phenotypes or antipsychotic resistance have received immunotherapy at the behest of distraught parents after counselling of treatment risks. We have been unsuccessful in helping those patients, and all are typically diagnosed with schizophrenia by our psychiatric colleagues. We fear that Pollak and colleagues' consensus will generate the expectation of immunotherapeutic cure for common idiopathic schizophreniform illnesses 1 The general autoimmune predilection among affective disorder cohorts (such as schizophrenia) supports immune-mediated injury during CNS development as risk for primary psychiatric illness later in life, by which time immune therapyresponsiveness has vanished. AM reports grants from Alexion, Grifols, and Euroimmun; and has patents pending for Septin-5-IgG, PDE10A-IgG, MAP1B-IgG, and GFAP-IgG. DD reports consulting fees paid to his employer from Astellas Research Institute of America. EF is principal investigator of a randomised placebo-controlled clinical trial of inebilizumab (CD19 inhibitor) in neuromyelitis optica spectrum disorders funded by MedImmune/Viela Bio and recieves reimbursement for research trial costs. SP reports grants, personal fees, non-financial support, and other from Alexion Pharmaceuticals and MedImmune; grants from Grifols, National Institutes of Health, and Autoimmune Encephalitis Alliance; consulting fees
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The Lancet Psychiatry, Thomas A Pollak and colleagues used criteria of paraneoplastic and autoimmune encephalitis to try to establish autoimmune psychosis as an identity by itself. 1 The most compelling reason they provided was that there are patients "having atypical, mild, or attenuated forms of autoimmune encephalitis".
The prominent neuronal surface antibodies found in patients with psychosis are those against the N-methyl-D-aspartate receptor (NMDAR), which block this receptor and cause psychosis in addition to symptoms associated with encephalitis. Only a small proportion of patients with anti-NMDAR encephalitis rely heavily on hard paraclinical investigations consistent with CNS inflammation. "Schizophreniform illnesses without additional features" would not meet these thresholds.
The nosological challenges that autoimmune psychosis faces are shared in considerable part by the other formes frustes which McKeon and colleagues propose: whereas McKeon and colleagues argue for the validity of autoimmune epilepsy and autoimmune dementia, Pilar Martinez-Martinez and Maarten J Titulaer warn against splitting of the autoimmune encephalitis construct along symptomatic lines. In the series that McKeon and colleagues cite, the majority of patients had other neurological or neuropsychiatric features in addition to seizures or dementia, which presented in isolation in only 34% and 29%, respectively. 2, 3 There is a tension between lumpers and splitters with regards to the correct nomenclature for CNS autoimmune disorders-as in many other areas of medicine. Although we (KB) first proposed a mild encephalitis hypothesis of some psychotic disorders years before the current era of neuronal surface antibody-mediated encephalopathies, 4 we believe that it remains an empirical question as to whether or not any of the proposed formes frustes of autoimmune encephalitis are in any substantial sense aetiologically different to autoimmune encephalitis: differences in epitope specificity, antibody titres and duration of interaction, initial immunising stimulus, or location of antibody synthesis (eg, intrathecal vs peripheral) might all turn out to be relevant.
Had current autoimmune encephalitis criteria captured the approach to patients with autoimmune psychosis in a way that reflected psychiatrists' clinical experience, there might have been no need for these guidelines, but unfortunately they did not. Presumably, a similar experience motivates clinicians proposing autoimmune epilepsy and have psychosis with only mild neurological symptoms, and having no neurological symptoms is even rarer. 2 These proportions are exemplified by Pollak and colleagues' study: the example patients in figures 1 and 2 had encephalitis, not merely autoimmune psychosis. 1 Although reports of patients with NMDAR antibodies who only developed psychosis have been published, 3 according to the criteria proposed by Pollak and colleagues, most of those patients would not have definite autoimmune psychosis, because, in most patients, antibody concentrations in the cerebrospinal fluid (CSF) were not measured. Measuring antibodies in serum alone with any cell-based assay (CBA) without validation is known to give false or irrelevant results, 4 as Pollak and colleagues acknowledge. Despite the good specificity, the low pretest probability of autoimmune encephalitis is responsible for only a moderate positive predictive value. In patients with psychosis without overt neurological symptoms, conservative calculations suggest that at least half of the patients with only a positive CBA in serum do not have autoimmune encephalitis (appendix). Therefore, in patients with psychosis, a careful assessment of additional subtle symptoms or other red flags is necessary. In those patients, it is mandatory to measure antibody concentrations in the CSF. Evidence that patients with antibodies in serum (but not in CSF) profit from immunotherapy is absent. Therefore, we think the category of probable autoimmune psychosis, as proposed by Pollak and colleagues, should not be used to consider immunotherapy.
Pollak and colleagues propose criteria in which one could replace the term psychosis for seizures, movement disorders, memory, or dysautonomia and these would fit perfectly. For these and other reasons, we do not endorse Pollak and colleagues' consensus. If the goal is to make psychiatrists aware that they should consider autoimmune encephalitis as a possible diagnosis, we think the best approach would be to discuss the diseases and the already established diagnostic approach, including red flags, instead of fragmenting them into symptoms (psychosis) and reinventing criteria for each of them (autoimmune psychosis and autoimmune epilepsy).
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